Select publications

Berry W et al. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001;28(4Suppl15):8-15. Abstract

Carroll PR et al. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology 2002;60(3Suppl1):1-6. Abstract

Dickie GJ, Macfarlane D. Strontium and samarium therapy for bone metastases from prostate carcinoma. Australas Radiol 1999;43(4):476-9. Abstract

Hudes GR et al. Phase II trial of 96-hour paclitaxel plus oral estramustine in metastatic hormone refractory prostate cancer. J Clin Oncol 1997:15(9);3156-63. Abstract

Hudes GR et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network Phase III trial. J Clin Oncol 1999;17;3160-66. Abstract

Kelly WK. Novel trial designs: Which agents and how do we test them? Urology 2002;60(3Suppl1):109-13;discussion113-4. Abstract

Kelly WK et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001;19(1):44-53. Abstract

Kreis W et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 1999;10 (5Suppl17):33-8. Abstract

Menda Y et al. Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain. Clin Nucl Med 2000;25(9):698-700. Abstract

Petrylak DP et al. Phase I trial of docetaxel with estramustine in androgen independent prostate cancer. J Clin Oncol 1999;17(3):958-67. Abstract

Savarese DM et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001;19(9):2509-16. Abstract

Smith DC et al. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 1999;17(6):1664-71. Abstract

Home

Editor’s Note

Gerald W Chodak, MD
    - Select publications

Thomas E Keane, MBBCh
    - Select publications

Frank A Vicini, MD
    - Select publications

William Kevin Kelly, DO
    - Select publications

Editor's Office